Journal
CURRENT OPINION IN ORGAN TRANSPLANTATION
Volume 16, Issue 2, Pages 180-187Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOT.0b013e3283446b1d
Keywords
cold storage; ex-vivo treatment; gene therapy; pharmacological supplementation; RNAi
Categories
Funding
- Conseil General de la Vienne
- Region Poitou Charentes
- Banque Tarneaud, Poitiers
- CHU de Poitiers
- Inserm
- Societe Francophone de Transplantation
- French Foundation of Transplantation
Ask authors/readers for more resources
Purpose of review In the current graft shortage, it is paramount to improve the quality of transplanted organs. Organ preservation represents an underused therapeutic window with great potential to reduce ischaemia-reperfusion injury (IRI) and improve graft quality. Herein, we review strategies using this window as well as other promising work targeting IRI pathways using pharmacological treatments and gene therapy. Recent findings We highlight studies using molecules administered during kidney preservation to target key components of IRI such as inflammation, oxidative stress, mitochondrial activity and the coagulation pathway. We further expose recent studies of gene therapy directed against inflammation or apoptosis during cold storage. Other pathways with potential therapeutic molecules are cited. Summary The use of cold preservation as a therapeutic window to deliver pharmacological or gene therapy treatments can significantly improve both short-term and long-term graft outcomes. Even if human gene therapy remains hampered by the quantity of agent needed and the potential harmfulness of the vector, it clearly offers a wide array of possibilities for the future. Although gene therapy is still too immature, we expose pharmacological strategies which can readily be applied to the clinic and improve both transplantation success rates and the patients' quality of life.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available